Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery

被引:31
作者
Ye, Tiantian [1 ]
Yuan, Kun [1 ]
Zhang, Wenji [1 ]
Song, Shuangshuang [1 ]
Chen, Fen [1 ]
Yang, Xinggang [1 ]
Wang, Shujun [1 ]
Bi, Jianwei [2 ]
Pan, Weisan [1 ,2 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharm, 103 Wenhua Rd, Shenyang 110016, Peoples R China
[2] Shangdong Wego Pharmaceut Co Ltd, Weihai 264209, Peoples R China
关键词
Ocular/ophthalmic drug delivery; Prodrugs; Nanocarriers; Penetration; Precorneal retention; Bioavailability;
D O I
10.1016/j.ajps.2013.09.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Numerous systems have been designed during the past three decades to improve bioavailability of ophthalmic drug delivery, including: ocular prodrugs and nanotechnology-based drug delivery system. The former can improve the efficacy of ocular drug via enhancing corneal penetration of ocular drugs, prolonging their duration of action and/or reducing the systemic side-effects, unfortunately, some characteristics of the prodrugs, such as poorly aqueous stability, poorly aqueous solubility and severe eye irritation probably, limit their clinical practice and cannot be ignored. As we all know, nanotechnology for ocular drug delivery can carry poorly soluble drugs, protect the encapsulated molecules from hydrolysis, control the rate of drug delivery and prolong the precorneal retention of drugs. All of these merits may solve the problems in the utilization of ocular prodrugs and increase the bioavailability of ocular drug delivery. By reviewing recent advances of prodrugs and nanostructures in ocular drug delivery, this paper focus specifically on the promising prospects of nanocarriers overcoming the drawbacks of prodrugs for ophthalmic drug delivery by precorneal routes. (c) 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All rights reserved.
引用
收藏
页码:207 / 217
页数:11
相关论文
共 85 条
  • [1] Influence of hydroxypropyl β-cyclodextrin on the corneal permeation of pilocarpine
    Aktas, Y
    Ünlü, N
    Orhan, M
    Irkeç, M
    Hincal, AA
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2003, 29 (02) : 223 - 230
  • [2] The potential of chitosan in ocular drug delivery
    Alonso, MJ
    Sánchez, A
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (11) : 1451 - 1463
  • [3] ANDERSON JA, 1980, INVEST OPHTH VIS SCI, V19, P817
  • [4] Chitosan based nanocarriers for indomethacin ocular delivery
    Badawi, Alia A.
    El-Laithy, Hanan M.
    El Qidra, Riad K.
    El Mofty, Hala
    El Dally, Mohamed
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2008, 31 (08) : 1040 - 1049
  • [5] Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
  • [6] BITO LZ, 1983, INVEST OPHTH VIS SCI, V24, P312
  • [8] ASSESSMENT OF TRANSPORT BARRIERS USING CELL AND TISSUE-CULTURE SYSTEMS
    BORCHARDT, RT
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1990, 16 (18) : 2595 - 2612
  • [9] When nanotechnology meets the ocular surface
    Bucolo, Claudio
    Maltese, Adriana
    Drago, Filippo
    [J]. EXPERT REVIEW OF OPHTHALMOLOGY, 2008, 3 (03) : 325 - 332
  • [10] PILOCARPINE PRODRUGS .1. SYNTHESIS, PHYSICOCHEMICAL PROPERTIES AND KINETICS OF LACTONIZATION OF PILOCARPIC ACID-ESTERS
    BUNDGAARD, H
    FALCH, E
    LARSEN, C
    MIKKELSON, TJ
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (01) : 36 - 43